地舒单抗治疗前列腺癌骨转移疼痛的临床研究  

Clinical study of Denosumab in the treatment of pain caused by bone metastasis of prostate cancer

作　　者：李想 陈炳 邬嘉波 吴海如 俞加法 LI Xiang;CHEN Bing;WU Jiabo;WU Hairu;YU Jiafa(Department of Urology,Zhoushan Hospital,Zhoushan 316000,Zhejiang,China)

机构地区：[1]舟山医院泌尿外科,浙江舟山316000

出　　处：《中国现代医生》2023年第18期14-17,56,共5页China Modern Doctor

基　　金：舟山市医药卫生科技计划项目(2021YA04)。

摘　　要：目的 探讨唑来膦酸和地舒单抗辅助去势疗法治疗前列腺癌骨转移疼痛的临床疗效。方法 选取舟山医院2022年1—6月收治的前列腺癌骨转移疼痛患者84例,采用随机数字表法分为对照组和试验组,每组各42例;两组均采用去势疗法治疗,对照组给予唑来膦酸辅助治疗,试验组采用地舒单抗治疗,比较两组的客观缓解率、治疗前后视觉模拟评分(visual analogue scale,VAS)、卡氏评分及安全性。结果 对照组和试验组客观缓解率分别为71.43%(30/42),80.95%(34/42);两组客观缓解率比较,差异无统计学意义(P>0.05)。两组治疗后3、6及12个月VAS评分均显著低于治疗前(P<0.05);试验组治疗后上述时间点VAS评分分别为(4.89±1.07)分、(2.26±0.71)分、(1.03±0.49)分,分别显著低于对照组的(5.68±1.32)分、(3.59±1.15)分、(1.95±0.65)分(P<0.05)。两组治疗后3、6及12个月卡氏评分均显著高于治疗前(P<0.05);试验组治疗后上述时间点卡氏评分分别为(60.69±6.65)分、(72.27±7.31)分、(80.10±9.57)分,均显著高于对照组的(55.36±4.97)分、(60.30±5.83)分、(69.65±7.45)分,差异有统计学意义(P<0.05)。对照组和试验组不良反应发生率分别为7.14%(3/42)、2.38%(1/42),两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论 相较于唑来膦酸,地舒单抗辅助去势疗法治疗前列腺癌骨转移疼痛可有效缓解疼痛症状,改善生活质量,且安全性良好。Objective To investigate the clinical efficacy of Zoledronic acid and Denosumab in the treatment of bone metastasis pain of prostate cancer.Methods A total of 84 patients with prostate cancer bone metastasis pain admitted to Zhoushan Hospital from January to June 2022 were randomly divided into control group and experimental group using the number table method,with 42 patients in each group.Both groups were treated with castration therapy,the control group was treated with zoledronic acid as an adjuvant therapy,and the test group was treated with Denosumab therapy.The objective remission rate,visual analogue scale(VAS)before and after treatment,Carlsberg score and safety of the two groups were compared.The objective response rates of the control group and the experimental group were 71.43%(30/42)and 80.95%(34/42),respectively;There was no statistically significant difference in objective response rates between the two groups(P>0.05).The VAS scores of both groups at 3,6,and 12 months after treatment were significantly lower than before treatment(P<0.05);After treatment,the VAS scores of the experimental group at the above time points were(4.89±1.07)points,(2.26±0.71)points,and(1.03±0.49)points,which were significantly lower than the control group’s(5.68±1.32)points,(3.59±1.15)points,and(1.95±0.65)points(P<0.05).After 3,6,and 12 months of treatment,the Karst scores of both groups were significantly higher than before treatment(P<0.05);After treatment,the Karst scores of the experimental group at the above time points were(60.69±6.65)points,(72.27±7.31)points,and(80.10±9.57)points,which were significantly higher than the control group’s(55.36±4.97)points,(60.30±5.83)points,and(69.65±7.45)points(P<0.05).The incidence of adverse reactions in the control group and the experimental group were 7.14%(3/42)and 2.38%(1/42),respectively.There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Compared with zoledronic acid,Denosumab assis

关 键 词：地舒单抗 唑来膦酸 去势疗法 前列腺癌 骨转移 疼痛 

分 类 号：R737.25[医药卫生—肿瘤]